A STING-activating nanovaccine boosts anti-tumor immunity in cancer immunotherapy28 and is able to inhibit expression of HPV E6/E7 in a tumor model, indicating that immune strategies targeting sensing of viral nucleic acids may be effective tumor growth inhibitors. The gene discussed is STING1; the disease is cancer.